Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.

In contrast, mice receiving the treatment combination showed a highly significant reduction in tumor masses compared to lorlatinib alone treatment already after 7 days of treatment (combination vs lorlatinib: median = 95 mm 3 vs 221 mm 3 , p-value = 0.001) and reached nearly complete regression of tumors at day 15 (median = 25 mm 3 vs 488 mm 3 , p = 0.00002) (Figure 6B and Supplementary Figure S5A ).

also in 132,142 other papers